Track topics on Twitter Track topics that are important to you
Iselin, NJ, June 29, 2017 --(PR.com)-- SMi Group has announced that Dr Cindy Cao, Executive Director and Head of US Regulatory Affairs for Biopharmaceuticals at Sandoz has joined the speaker panel for the 4th Biosimilars North America, which takes place on November 15 & 16, 2017.
Earlier this year, the FDA released a highly-anticipated draft of guidelines for biosimilar interchangeability. Months later, more than 50 stakeholder groups have submitted comments on the draft guidance. Comments suggested that the agency still needs to clarify the standards for naming and labelling, as well as showing that a biosimilar is, indeed, interchangeable with the original biologic. Dr Cao’s presentation will aim to address questions relating to the FDA guidelines.
Speaking on Day 1 of the conference, Dr Cao will discuss the FDA's biosimilar interchangeability guidance. In her presentation, she will discuss the impact of the new guidelines and explore considerations for interchangeability, as well as how to engage with stakeholders.
Dr Cao joins a speaker lineup comprised of experts shaping up the biosimilars landscape in North America including representatives from Sandoz, Mylan, Harvest Moon Pharmaceuticals, Momenta, FUJIFILM Diosynth, Oncobiologics, Adelio, Covance, Zuckerman & Spaeder and more.
The full roster of speakers and their topics can be found on www.biosimilars-northamerica.com/prcom.
This year, the conference will also explore significant developmental topics within the sector including the impact of FDA’s newly implemented biosimilar interchangeability guidelines, the US market access landscape, and biosimilars of orphan drugs.
Registration is now live on the event website and there are currently Early Bird rates available.
4th Biosimilars North America
November 15 & 16, 2017
Renaissance Woodbridge Hotel, Iselin, NJ, USA
For delegate registration enquiries, contact Fateja Begum on firstname.lastname@example.org. For media enquiries, contact Honey de Gracia at email@example.com.
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk
Honey de Gracia
+44 (0) 207 827 6102
Contact via Email
Read the full story here: http://www.pr.com/press-release/721481
Press Release Distributed by PR.com
BioPortfolio lists over 550 biotechnology products - please open http://www.bioportfolio.com/channels?category_id=5 Direct topic pages: Actos Advair Biopharmaceuticals Biosimilars Biotherapeutics GMO Crops Lipitor ...
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...
Biosimilars or Follow-on biologics are terms used to describe officially approved subsequent versions of innovator biopharmaceutical products made by a different sponsor following patent and exclusivity expiry on the innovator product. Products that ar...